Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study
Age over 18, with Hodgkin’s lymphoma or with large B and P cell non-Hodgkin’s lymphoma, or
after a first-line chemotherapy with at least a residual mass or after induction
chemotherapy or at progression.
Stem cell transplantation would be programmed. Patients were required to give their
written informed consent.
Progressive cancer or diagnosed less than 5 years, except cancer in situ of the cervix and
basocell skin carcinoma, kidney insufficiency or diabetes. Patients would not be pregnant
Type of Study:
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
The impact of positron emission tomography (PET) using fluorine-18-floro-deoxyglucose (FDG) in the therapeutic prescription in patients with Hodgkin’s lymphoma or with large B and P cell non-Hodgkin’s lymphoma.
Gilles SALLES, MD
Hospices Civils de Lyon
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
- positron emission tomography
- stem cell transplantation
- therapeutic impact